Crohn's Disease Clinical Trials

31 trials recruiting in Canada.

Digestive Health

Recruiting Drug Device Behavioral Older adults Healthy volunteers

31 trials · showing 30

Comparing Tirzepatide with Mirikizumab for Crohn's disease

Explore this study →

There are 2 groups in this study. Group A receives Mirikizumab and Tirzepatide. Group B receives Mirikizumab and Placebo.

Sites in London, Vancouver and 3 more cities

Phase 3
2 groups
Sites in Edmonton, London and 3 more cities
Recruiting

Official title: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Crohn's Disease · Eli Lilly and Company

Comparing Mirikizumab - with LY4395089 for crohn disease

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives one or more of: Mirikizumab - Intravenous (IV) and Mirikizumab - Subcutaneous (SC). Group B receives LY4395089, together with one or more of: Mirikizumab - Intravenous (IV) and Mirikizumab - Subcutaneous (SC).

Sites in Greenfield Park, Lethbridge and 2 more cities

Phase 2
2 groups
Sites in Greenfield Park, Lethbridge and 2 more cities
Recruiting

Official title: A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

Crohn Disease · Eli Lilly and Company

Comparing 5 approaches for Crohn's disease

Explore this study →

There are 5 groups in this study. Groups A, B, C, D and E receive Guselkumab.

Sites in Halifax, London and 1 more city

Phase 3
5 groups
Sites in Halifax, London and 1 more city
Recruiting

Official title: A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease · Janssen Research & Development, LLC

Get matched to the best-fit trials

Answer a few questions and we'll find the closest matches for crohn's disease.

Comparing Guselkumab with Risankizumab for crohn disease

Explore this study →

There are 2 groups in this study. Group A receives Guselkumab. Group B receives Risankizumab.

Sites in Montreal, Edmonton and 5 more cities

Phase 3
2 groups
Sites in Edmonton, Vancouver and 5 more cities
Recruiting

Official title: A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Crohn Disease · Janssen Research & Development, LLC

Testing Icotrokinra against a placebo for crohn disease

Explore this study →

There are 8 groups in this study. Groups A, B, D, F and G receive Icotrokinra. Groups C and E, the placebo group, receive Placebo. Group H, the placebo group, receives Placebo, together with one or more of: Icotrokinra.

Sites in Edmonton, Barrie and 6 more cities

Phase 2
8 groups
Sites in Edmonton, Vancouver and 6 more cities
Recruiting

Official title: A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

Crohn Disease · Janssen Research & Development, LLC

Comparing JNJ-78934804 with Guselkumab for crohn disease

Explore this study →

There are 2 groups in this study. Group A receives JNJ-78934804. Group B, the comparison group, receives Guselkumab, together with one or more of: JNJ-78934804.

Sites in Edmonton, Montreal and 7 more cities

Phase 3
2 groups
Sites in Edmonton, Vancouver and 7 more cities
Recruiting

Official title: A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

Crohn Disease · Janssen Research & Development, LLC

Comparing 4 approaches for Crohn's disease

Explore this study →

There are 4 groups in this study. Groups A and B receive TAK-279, together with one or more of: Placebo. Group C receives TAK-279. Group D receives Placebo.

Sites in London, Montreal and 4 more cities

Phase 2
4 groups
Sites in Calgary, New Westminster and 4 more cities
Recruiting

Official title: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease · Takeda

Testing IV Tulisokibart against a placebo for Crohn's disease

Explore this study →

There are 11 groups in this study. Group A receives one or more of: IV Tulisokibart and SC Tulisokibart. Groups B and C receive one or more of: IV Tulisokibart, SC Tulisokibart and SC Placebo. Groups D and I, the placebo group, receive one or more of: IV Tulisokibart, IV Placebo and SC Placebo. …and 4 more groups.

Sites in London, Montreal and 13 more cities

Phase 3
11 groups
Sites in Calgary, Edmonton and 13 more cities
Recruiting

Official title: A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Crohn's Disease · Merck Sharp & Dohme LLC

Comparing 22 approaches for Crohn's disease

Explore this study →

There are 22 groups in this study. Groups A, B, K and L receive Risankizumab. Groups C, D, E and F receive Trosunilimab. Groups G, H, I and J receive Risankizumab and Trosunilimab. …and 2 more groups.

One site, in Québec

Phase 2
22 groups
One site, in Québec
Recruiting

Official title: Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

Crohn's Disease · AbbVie

Comparing 3 approaches for crohn disease

Explore this study →

There are 3 groups in this study. Group A, the comparison group, receives one or more of: TNFa Antagonist - Infliximab and TNFa Antagonist - Adalimumab. Group B, the comparison group, receives one or more of: Anti-IL12/23 or anti-IL23 - Ustekinumab and Anti-IL12/23 or anti-IL23 - Risankizumab. Group C, the comparison group, receives one or more of: Anti-integrin - Vedolizumab IV and Anti-integrin - Vedolizumab IV and SC.

Sites in Montreal, Brampton and 14 more cities

Phase 4
3 groups
Sites in Calgary, Edmonton and 14 more cities
Recruiting

Official title: PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease

Crohn Disease · University of Calgary

Testing Afimkibart against a placebo for moderately to severely active crohns disease

Explore this study →

There are 2 groups in this study. Group A receives Afimkibart. Group B, the placebo group, receives Placebo.

Sites in London, Barrie and 3 more cities

Phase 3
2 groups
Sites in Barrie, Brampton and 2 more cities
Recruiting

Official title: A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Moderately to Severely Active Crohns Disease · Hoffmann-La Roche

Testing Mirikizumab for crohn disease

Explore this study →

Everyone in this study is in one group and receives Mirikizumab.

Sites in Hamilton, London and 2 more cities

Phase 4
1 group
Sites in Vancouver, Hamilton and 2 more cities
Recruiting

Official title: Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD

Crohn Disease · Alimentiv Inc.

Testing Duvakitug against a placebo for Crohn's disease

Explore this study →

There are 3 groups in this study. Groups A and B receive Duvakitug. Group C, the placebo group, receives Placebo.

Sites in London, Montreal and 7 more cities

Phase 3
3 groups
Sites in Oakville, Brampton and 7 more cities
Recruiting

Official title: An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease · Sanofi

Testing Duvakitug against a placebo for Crohn's disease

Explore this study →

There are 4 groups in this study. Groups A, B and C receive Duvakitug. Group D, the placebo group, receives Placebo.

Sites in Edmonton, Hamilton and 3 more cities

Phase 3
4 groups
Sites in Edmonton, Hamilton and 3 more cities
Recruiting

Official title: A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease · Sanofi

Comparing 15 approaches for Crohn's disease

Explore this study →

There are 15 groups in this study. Groups A, B, C, D, E, F, G, H, I, J, K, L, M, N and O receive Risankizumab.

Sites in Calgary, Edmonton and 2 more cities

Phase 3
15 groups
Sites in Calgary, Edmonton and 2 more cities
Recruiting

Official title: A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease · AbbVie

Testing Afimkibart against a placebo for moderately to severely active crohns disease

Explore this study →

There are 3 groups in this study. Groups A and B receive Afimkibart. Group C, the placebo group, receives Placebo.

Sites in Edmonton, Trois-Rivières and 1 more city

Phase 3
3 groups
Sites in Edmonton, Vaughan and 1 more city
Recruiting

Official title: A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Moderately to Severely Active Crohns Disease · Hoffmann-La Roche

Comparing 3 approaches for Crohn's disease

Explore this study →

There are 3 groups in this study. Groups A, B and C receive Mirikizumab.

Sites in Halifax, London and 2 more cities

Phase 3
3 groups
Sites in Halifax, London and 2 more cities
Recruiting

Official title: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Crohn's Disease · Eli Lilly and Company

TIDHI Mental Health in IBD Patients Study

Explore this study →

There are 2 groups in this study. Group A receives Healing Circuits™ sessions. Group B receives self-directed Healing Circuits™ curriculum.

One site, in North York

2 groups
Recruiting

Crohn Disease (CD) · TIDHI Innovation Inc.

Comparing 8 approaches for Crohn's disease

Explore this study →

There are 8 groups in this study. Groups A and H receive Risankizumab. Groups B and G receive Risankizumab and Trosunilimab. Group C receives Trosunilimab. …and 3 more groups.

Sites in Edmonton, Calgary and 5 more cities

Phase 2
8 groups
Sites in Calgary, Edmonton and 5 more cities
Recruiting

Official title: Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

Crohn's Disease · AbbVie

Comparing 3 approaches for Crohn's disease

Explore this study →

There are 3 groups in this study. Group A receives Vedolizumab and Adalimumab. Group B receives Vedolizumab and Ustekinumab. Group C receives Vedolizumab.

Sites in Edmonton, London and 5 more cities

Phase 4
3 groups
Sites in Edmonton, London and 4 more cities
Recruiting

Official title: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Crohn's Disease · Takeda

Testing Dietary Intakes (Reference protein for crohn disease

Explore this study →

Everyone in this study is in one group and receives Dietary Intakes (Reference protein drinks (Scandishake, Solcarb, Beneprotein) and cookies).

One site, in Toronto

1 group
One site, in Toronto
Recruiting

Official title: Threonine Requirement in Adult Males With Crohn's Disease Using IAAO

Crohn Disease · The Hospital for Sick Children

Comparing 9 approaches for Crohn's disease (CD)

Explore this study →

There are 9 groups in this study. Groups A, B, C, D, E, F, G, H and I receive Vedolizumab IV.

Sites in Edmonton, London and 2 more cities

Phase 3
9 groups
Sites in Edmonton, Vancouver and 2 more cities
Recruiting

Official title: A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Crohn's Disease (CD) · Takeda

Testing Anti-TNF therapy for crohn disease

Explore this study →

Everyone in this study is in one group and receives Anti-TNF therapy.

Sites in Edmonton, London and 2 more cities

Phase 4
1 group
Sites in Edmonton, London and 2 more cities
Recruiting

Official title: Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

Crohn Disease · Connecticut Children's Medical Center

Comparing Whole-food based smoothie with Formula for crohn disease

Explore this study →

There are 2 groups in this study. Group A receives Whole-food based smoothie. Group B, the comparison group, receives Formula.

One site, in Halifax

2 groups
One site, in Halifax
Recruiting

Official title: Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial

Crohn Disease · Seattle Children's Hospital

Testing Vedolizumab against a placebo for Crohn's disease

Explore this study →

There are 3 groups in this study. Group A receives Vedolizumab and Upadacitinib. Group B, the placebo group, receives Vedolizumab and Placebo. Group C receives Vedolizumab.

Sites in Barrie, Calgary and 7 more cities

Phase 3
3 groups
Sites in Calgary, Winnipeg and 7 more cities
Recruiting

Official title: A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

Crohn's Disease · Takeda

Testing Vedolizumab for moderately to severely active Crohn's disease

Explore this study →

There are 2 groups in this study. Groups A and B receive Vedolizumab.

Sites in London, Bridgewater and 3 more cities

Phase 4
2 groups
Sites in Calgary, Edmonton and 3 more cities
Recruiting

Official title: VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

Moderately to Severely Active Crohn's Disease · Alimentiv Inc.

Comparing KleanLyte with Bi-PegLyte for crohn disease

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives KleanLyte. Group B, the comparison group, receives Bi-PegLyte.

One site, in Winnipeg

Phase 4
2 groups
One site, in Winnipeg
Recruiting

Official title: Bowel Preparation for Colonoscopy Among Individuals With Crohn's and Ulcerative Colitis Disease.

Crohn Disease · University of Manitoba

Comparing 6 approaches for Crohn's disease

Explore this study →

There are 6 groups in this study. Groups A, B, C, D, E and F receive Upadacitinib.

Sites in Halifax, Montreal and 1 more city

Phase 3
6 groups
Sites in Vancouver, Halifax and 1 more city
Recruiting

Official title: Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

Crohn's Disease · AbbVie

Testing SAR441566 against a placebo for Crohn's disease

Explore this study →

There are 4 groups in this study. Groups A, B and C receive SAR441566. Group D, the placebo group, receives SAR441566 matching Placebo.

Sites in Calgary, Montreal and 1 more city

Phase 2
4 groups
Sites in Calgary, Montreal and 1 more city
Recruiting

Official title: A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.

Crohn's Disease · Sanofi

Testing Ustekinumab for crohn disease (CD)

Explore this study →

There are 2 groups in this study. Group A receives Ustekinumab 90 mg SC q8w. Group B receives Ustekinumab 90 mg SC q12w.

One site, in Montreal

Phase 4
2 groups
One site, in Montreal
Recruiting

Official title: De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis

Crohn Disease (CD) · McGill University Health Centre/Research Institute of the McGill University Health Centre

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Crohn's Disease trials near you.

← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.